{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:56:13Z","timestamp":1792302973427,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2006,6,2]],"date-time":"2006-06-02T00:00:00Z","timestamp":1149206400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s10067-006-0203-8","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T19:04:32Z","timestamp":1149188672000},"page":"22-29","source":"Crossref","is-referenced-by-count":103,"title":["Update on guidelines for the treatment of chronic musculoskeletal pain"],"prefix":"10.1007","volume":"25","author":[{"given":"Thomas J.","family":"Schnitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,6,2]]},"reference":[{"key":"203_CR1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0140-6736(99)03057-3","volume":"354","author":"AM Elliott","year":"1999","unstructured":"Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA (1999) The epidemiology of chronic pain in the community. Lancet 354:1248\u20131252","journal-title":"Lancet"},{"issue":"5 Suppl","key":"203_CR2","first-page":"S6","volume":"180","author":"LM March","year":"2004","unstructured":"March LM, Bagga H (2004) Epidemiology of osteoarthritis in Australia. Med J Aust 180(5 Suppl):S6\u2013S10","journal-title":"Med J Aust"},{"key":"203_CR3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2036.1997.d01-604.x","volume":"11","author":"AL Blower","year":"1997","unstructured":"Blower AL, Brooks A, Fenn GC et al (1997) Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 11:283\u2013291","journal-title":"Aliment Pharmacol Ther"},{"key":"203_CR4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0304-3959(03)00020-4","volume":"104","author":"F Boureau","year":"2003","unstructured":"Boureau F, Legallicier P, Kabir-Ahmadi M (2003) Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 104:323\u2013331","journal-title":"Pain"},{"key":"203_CR5","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1097\/00007632-200010010-00013","volume":"25","author":"MW Tulder van","year":"2000","unstructured":"van Tulder MW, Scholten RJ, Koes BW, Deyo RA (2000) Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine 25:2501\u20132513","journal-title":"Spine"},{"key":"203_CR6","doi-asserted-by":"crossref","unstructured":"van Tulder MW, Scholten RJ, Koes BW, Deyo RA (2000) Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev (2):CD000396","DOI":"10.1002\/14651858.CD000396"},{"key":"203_CR7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ard.56.4.214","volume":"56","author":"BW Koes","year":"1997","unstructured":"Koes BW, Scholten RJ, Mens JM, Bouter LM (1997) Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Ann Rheum Dis 56:214\u2013223","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 56","key":"203_CR8","first-page":"18","volume":"26","author":"G Singh","year":"1999","unstructured":"Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26(Suppl 56):18\u201324","journal-title":"J Rheumatol"},{"key":"203_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3959(99)00267-5","volume":"85","author":"MR Tramer","year":"2000","unstructured":"Tramer MR, Moore RA, Reynolds DJ, McQuay HJ (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85:169\u2013182","journal-title":"Pain"},{"key":"203_CR10","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","volume":"354","author":"P Emery","year":"1999","unstructured":"Emery P, Zeidler H, Kvien TK et al (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354:2106\u20132111","journal-title":"Lancet"},{"key":"203_CR11","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0149-2918(99)80045-9","volume":"21","author":"K Malmstrom","year":"1999","unstructured":"Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ (1999) Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 21:1653\u20131663","journal-title":"Clin Ther"},{"key":"203_CR12","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","volume":"117","author":"L Laine","year":"1999","unstructured":"Laine L, Harper S, Simon T et al (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117:776\u2013783","journal-title":"Gastroenterology"},{"key":"203_CR13","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0149-2918(99)80048-4","volume":"21","author":"TJ Schnitzer","year":"1999","unstructured":"Schnitzer TJ, Truitt K, Fleischmann R et al (1999) The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 21:1688\u20131702","journal-title":"Clin Ther"},{"key":"203_CR14","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","volume":"43","author":"American College of Rheumatology Subcommittee on Osteoarthritis Guidelines","year":"2000","unstructured":"American College of Rheumatology Subcommittee on Osteoarthritis Guidelines (2000) Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43:1905\u20131915","journal-title":"Arthritis Rheum"},{"key":"203_CR15","first-page":"179","volume-title":"Pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. In: Clinic practice guideline, no. 2","author":"LS Simon","year":"2002","unstructured":"Simon LS, Lipman AG, Jacox AK et al (2002) Pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. In: Clinic practice guideline, no. 2. American Pain Society (APS), Glenview, IL, pp 179"},{"key":"203_CR16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2003.011742","volume":"62","author":"KM Jordan","year":"2003","unstructured":"Jordan KM, Arden NK, Doherty M et al (2003) EULAR recommendations 2003: an evidence-based approach to the management of knee osteoarthritis [Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)]. Ann Rheum Dis 62:1145\u20131155","journal-title":"Ann Rheum Dis"},{"key":"203_CR17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520\u20131528","journal-title":"N Engl J Med"},{"key":"203_CR18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092\u20131102","journal-title":"N Engl J Med"},{"key":"203_CR19","unstructured":"Merck press release. Merck announces voluntary worldwide withdrawal of Vioxx. http:\/\/www.vioxx.com\/rofecoxib\/vioxx\/consumer\/press_release_09302004.jsp . Accessed November 2005"},{"key":"203_CR20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Adenoma Prevention with Celecoxib (APC) Study Investigators et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071\u20131080","journal-title":"N Engl J Med"},{"key":"203_CR21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5223(03)00125-9","volume":"125","author":"E Ott","year":"2003","unstructured":"Ott E, Nussmeier NA, Duke PC, Multicenter Study of Perioperative Ischemia (McSPI) Research Group, Ischemia Research and Education Foundation (IREF) Investigators et al (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125:1481\u20131492","journal-title":"J Thorac Cardiovasc Surg"},{"key":"203_CR22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"NA Nussmeier","year":"2005","unstructured":"Nussmeier NA, Whelton AA, Brown MT et al (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081\u20131091","journal-title":"N Engl J Med"},{"key":"203_CR23","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","volume":"330","author":"J Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366","journal-title":"BMJ"},{"issue":"9494","key":"203_CR24","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(05)67488-0","volume":"366","author":"J Sudbo","year":"2005","unstructured":"Sudbo J, Lee JJ, Lippman SM et al (2005) Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet 366(9494):1359\u20131366","journal-title":"Lancet"},{"key":"203_CR25","unstructured":"FDA talk paper. FDA issues public health advisory recommending limited use of COX-2 inhibitors. December 2004. Downloaded November 2005. http:\/\/www.fda.gov\/bbs\/topics\/ANSWERS\/2004\/ANS01336.html"},{"key":"203_CR26","unstructured":"EMEA press statement, 17 February 2005 European Medicines Agency announces regulatory action on COX-2 inhibitors. http:\/\/www.emea.eu.int\/pdfs\/human\/press\/pr\/6275705en.pdf . Accessed November 2005"},{"key":"203_CR27","unstructured":"FDA memorandum, April 6, 2005. Downloaded November 2005. http:\/\/www.fda.gov\/cder\/drug\/infopage\/COX2\/NSAIDdecisionMemo.pdf"},{"key":"203_CR28","unstructured":"FDA public health advisory. FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). April 7, 2005. Downloaded November 2005. http:\/\/www.fda.gov\/cder\/drug\/advisory\/COX2.htm"},{"key":"203_CR29","unstructured":"EMEA press release, 27 June 2005. European Medicines Agency concludes action on COX-2 inhibitors. http:\/\/www.emea.eu.int\/pdfs\/human\/press\/pr\/20776605en.pdf . Accessed November 2005"},{"key":"203_CR30","unstructured":"EMEA press statement, 7 April 2005. European Medicines Agency statement on the suspension of use of Bextra. http:\/\/www.emea.eu.int\/htms\/hotpress\/h12163705.htm . Accessed November 2005"},{"key":"203_CR31","unstructured":"EMEA press release, 2 August 2005. Accessed November 2005"},{"key":"203_CR32","unstructured":"EMEA press release, 17 October 2005. European Medicines Agency update on non-selective NSAIDs. http:\/\/www.emea.eu.int\/pdfs\/human\/press\/pr\/29896405en.pdf . Accessed November 2005"},{"key":"203_CR33","doi-asserted-by":"crossref","unstructured":"Towheed TE, Maxwell L, Anastassiades TP et al (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev (2):CD002946","DOI":"10.1002\/14651858.CD002946.pub2"},{"key":"203_CR34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.joca.2004.01.004","volume":"12","author":"D Uebelhart","year":"2004","unstructured":"Uebelhart D, Malaise M, Marcolongo R et al (2004) Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil 12:269\u2013276","journal-title":"Osteoarthr Cartil"},{"key":"203_CR35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pds.842","volume":"12","author":"N Moore","year":"2003","unstructured":"Moore N, Charlesworth A, Van Ganse E et al (2003) Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf 12:601\u2013610","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"203_CR36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","volume":"110","author":"E Selvin","year":"2004","unstructured":"Selvin E, Erlinger TP (2004) Prevalence of and risk factors for peripheral arterial disease in the United States. Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110:738\u2013743","journal-title":"Circulation"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-006-0203-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0203-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:50:56Z","timestamp":1559119856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-006-0203-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,2]]},"references-count":36,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1007\/s10067-006-0203-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,2]]}}}